This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on NA Companies: vTv Therapeutics (VTVT), TripAdvisor (TRIP) and Caris Life Sciences, Inc. (CAI)

Tipranks - Tipranks - Sat Aug 8, 6:15AM CDT

Analysts have been eager to weigh in on the NA sector with new ratings on vTv Therapeutics (VTVT), TripAdvisor (TRIP) and Caris Life Sciences, Inc. (CAI).

Claim 55% Off TipRanks

vTv Therapeutics (VTVT)

In a report released yesterday, Kambiz Yazdi from BTIG maintained a Buy rating on vTv Therapeutics, with a price target of $57.00. The company’s shares closed last Thursday at $34.61.

According to TipRanks.com, Yazdi is a 5-star analyst with an average return of 30.8% and a 71.4% success rate. Yazdi covers the Healthcare sector, focusing on stocks such as Praxis Precision Medicines, Zevra Therapeutics, and Kazia Therapeutics. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for vTv Therapeutics with a $57.67 average price target, representing a 67.5% upside. In a report issued on July 31, Roth MKM also maintained a Buy rating on the stock with a $58.00 price target.

See the top stocks recommended by analysts >>

TripAdvisor (TRIP)

In a report released yesterday, Jake Fuller from BTIG maintained a Hold rating on TripAdvisor. The company’s shares closed last Thursday at $10.42.

According to TipRanks.com, Fuller is a 4-star analyst with an average return of 7.0% and a 52.0% success rate. Fuller covers the NA sector, focusing on stocks such as Booking Holdings, Maplebear, and DoorDash. ;'>

The word on The Street in general, suggests a Hold analyst consensus rating for TripAdvisor with a $14.32 average price target, implying a 30.9% upside from current levels. In a report issued on July 30, UBS also maintained a Hold rating on the stock with a $15.00 price target.

Caris Life Sciences, Inc. (CAI)

In a report released yesterday, Mark Massaro from BTIG reiterated a Buy rating on Caris Life Sciences, Inc., with a price target of $33.00. The company’s shares closed last Thursday at $20.00.

According to TipRanks.com, Massaro is a 4-star analyst with an average return of 4.1% and a 37.4% success rate. Massaro covers the Healthcare sector, focusing on stocks such as Insight Molecular Diagnostics, Adaptive Biotechnologies, and Tempus AI, Inc. Class A. ;'>

Caris Life Sciences, Inc. has an analyst consensus of Strong Buy, with a price target consensus of $27.00, which is a 42.1% upside from current levels. In a report released yesterday, J.P. Morgan also maintained a Buy rating on the stock with a $25.00 price target.

Read More on VTVT:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).